| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Revenue | $87.4M | -77.1% |
| Cost of Revenue | $6.0M | -76.6% |
| R&D Expense | $104.1M | -18.8% |
| SG&A Expense | $114.3M | -39.3% |
| Operating Income | -$314.7M | -911.1% |
| Pre-tax Income | -$302.1M | -656.5% |
| Income Tax | -$393K | -107.8% |
| Net Income | -$301.7M | -712.4% |
| EPS (Basic) | -$4.43 |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $77.4M | -54.5% |
| Short-term Investments | $99.1M | -50.7% |
| Accounts Receivable | $447K | -98.9% |
| Inventory | $38.3M | +0.0% |
| Current Assets | $189.4M | -59.2% |
| Total Assets | $193.6M | -62.6% |
| Current Liabilities | $28.4M | -65.4% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$167.6M | -1506.6% |
| Capital Expenditures | $157K | -87.3% |
| Investing Cash Flow | $75.7M | -17.8% |
| Financing Cash Flow | $348K | -90.2% |
| Free Cash Flow | -$167.8M | -1671.5% |
| -706.8% |
| EPS (Diluted) | -$4.43 | -732.9% |
| Total Liabilities |
| $28.9M |
| -65.6% |
| Stockholders' Equity | $164.8M | -62.0% |